摘要 |
Disclosed are methods for inhibiting bone resorption in mammals wile minimizing the occurrence of or potential for adverse gastrointestinal effects.The method is characterized by administering a unit dosage, which comprises a pharmaceutically acceptable amount of a alendronic comprising about 70 mg on an alendronic acid active basis, according to a continuous schedule having a dosing interval of once-weekly dosing.The compounds are alendronate, cimadronate, clodronate, tiludronate, etridronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, optionally in combination with a histamine H2 antagonist. |